Evotec, Variant Bio Announce Collaboration Agreement To Identify Treatment For Diseases Caused By Fibrosis.
Portfolio Pulse from Benzinga Newsdesk
Evotec and Variant Bio have entered into a collaboration agreement to discover treatments for diseases caused by fibrosis. Evotec will receive research funding, with potential for pre-clinical and clinical milestones and/or royalties based on the program's success.
April 18, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evotec enters a collaboration with Variant Bio to develop fibrosis treatments, receiving research funding and potential future payments.
The collaboration with Variant Bio could open up new revenue streams for Evotec through research funding and potential milestone payments and royalties. This partnership indicates progress in Evotec's pipeline development and could positively influence investor sentiment.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90